San Francisco Expanded Doxy-PEP Eligibility
The city updated its guidance in May to allow cisgender women and others assigned female at birth to access the medication.
Updated on Oct. 14, 2026 in Sexual Health
Live Poll
Is expanding antibiotic use for STI prevention a safe approach for your community?
In May 2026, San Francisco health officials expanded eligibility for doxy-PEP to include cisgender women and others assigned female at birth. The city now permits clinicians to offer the medication based on individual risk assessments.
Why it matters
The change aims to prevent bacterial STIs and congenital syphilis by leveraging studies from Japan and Kenya that support the treatment's efficacy in cisgender women. This policy update broadens access beyond the current CDC focus on men who have sex with men and transgender women.
Doxy-PEP involves a single 200-milligram dose of doxycycline taken within 72 hours of sexual activity. Eligibility is determined through shared decision-making regarding a patient's risk factors.
The players
Centers for Disease Control and Prevention
This federal agency provides national health guidance and currently recommends doxy-PEP primarily for men who have sex with men and transgender women.
The details
Clinicians in San Francisco are now authorized to discuss the preventive regimen with patients who meet specific risk criteria. The move follows successful city-wide infection rate declines observed in 2025.
Timeline
October 2022: San Francisco issued the nation's first doxy-PEP guidance.
2024: Baseline year for city infection rate comparisons.
2025: San Francisco reported drops in syphilis, chlamydia, and gonorrhea.
May 2026: San Francisco updated its doxy-PEP guidance.
Health Landscape
San Francisco's decision marks a policy departure from the narrower guidelines set by the CDC regarding doxy-PEP implementation. This expansion highlights a divergence between local health initiatives and broader national standards for bacterial STI prevention.
Cisgender women and others assigned female at birth who meet risk criteria can now discuss doxy-PEP as a preventative option with their local clinicians. Patients should engage in shared decision-making with their providers to evaluate their specific needs and risks.
The takeaway
This policy change reflects a growing commitment to using post-exposure prophylaxis to address rising STI rates. Residents should consult their healthcare providers to determine if this preventative medication is appropriate for their individual health circumstances.
Further reading
Learn more about local public health efforts at San Francisco Sexual Health.
Source note: This article includes information reported by Medical Daily.
Live Poll
Is expanding antibiotic use for STI prevention a safe approach for your community?
